3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
CNS
1
Conditions
Lung Neoplasms
11
Carcinoma, Non-Small-Cell Lung
3
Smoking Cessation
2
Disease
2
Colorectal Neoplasms
2
Solitary Pulmonary Nodule
1
Pulmonary Disease, Chronic Obstructive
1
Prostatic Neoplasms
1
Pancreatic cancer, adult
1
Ovarian Neoplasms
1
Neoplasms
1
Motor Activity
1
Inflammation
1
Glioblastoma
1
Cardiovascular Diseases
1
Carcinoma, Hepatocellular
1
Adenocarcinoma of Lung
1
Interventions
pembrolizumab
3
Paclitaxel
3
Nivolumab
2
Drug Therapy
2
Bevacizumab
2
Azacitidine
2
vocimagene amiretrorepvec
1
ulixertinib
1
spartalizumab
1
sacituzumab govitecan
1
ruxolitinib
1
rucaparib
1
regorafenib
1
pazopanib
1
motexafin gadolinium
1
fludarabine
1
erythromycin propionate-N-acetylcysteinate
1
epacadostat
1
depatuxizumab mafodotin
1
cobimetinib
1
cediranib
1
cc-486
1
carboxyamido-triazole
1
capmatinib
1
bemcentinib
1
aflibercept
1
abiraterone
1
abemaciclib
1
Uncertainty
1
Thalidomide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Glioblastoma
×
Hematologic Tests
×
Thoracic
×
Clear all
NCT06717295
2026-01-02
CCANED-CIPHER
Dysplasia Diagnostics Limited
Recruiting
6,000 enrolled